Any uninsured patient considering long-term GLP-1 therapy should undergo baseline metabolic and renal assessment
Ready to source pharmaceutical-grade IGF-1 LR3
Mechanism of retatrutide receptor interaction According to the results of preclinical and clinical studies, retatrutide acts as a triple agonist of the GLP-1, GIP and GCGR receptors, influencing the regulation of appetite, glucose metabolism and energy expenditure
Visceral fat refers to adipose tissue stored deep within the abdominal cavity, surrounding vital organs including the liver, pancreas, and intestines
Monitor blood sugar, weight loss progress, and any side effects, particularly gastrointestinal symptoms